Therapeutic delivery of VEGF-C increases checkpoint inhibitor therapy to eradicate existing glioblastoma multiforme by increasing T cell priming and improving anti-tumor immunity, rather than inducing metastasis through lymphangiogenesis [80]. This evidence concerns the gene VEGFC and glioblastoma.